# US 10,864,269 B2 · Therapeutic combinations comprising anti-CD73 antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,269 B2
- Document ID: US10864269B2
- Status: Granted
- Kind: B2
- Application number: 15/714,536
- Filed: 2017-09-25
- Published: 2018-05-10
- Granted: 2020-12-15
- Earliest claimed: 2014-11-11
- Assignees: MedImmune, LLC
- Applicants: MedImmune Limited
- Inventors: Kris Sachsenmeier; Erin Sult; Carl Hay; Edmund Poon
- Web page: https://patentgrep.com/patent/US10864269B2

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.

## Claims

### Claim 1

A method of inhibiting tumor growth in a subject comprising administering an anti-CD73 antibody, wherein the anti-CD73 antibody is MEDI9447 or an antigen-binding fragment thereof, and an adenosine receptor inhibitor (A2Ari) for inhibiting tumor growth to the subject.

### Claim 2

A method of increasing an anti-tumor immune response comprising administering an anti-CD73 antibody, wherein the anti-CD73 antibody is MEDI9447 or an antigen-binding fragment thereof, and an adenosine receptor inhibitor (A2Ari) to a subject in need thereof.

### Claim 3

A method of treating a tumor in a subject comprising administering to the subject an anti-CD73 antibody, wherein the anti-CD73 antibody is MEDI9447 or an antigen-binding fragment thereof, and an adenosine receptor inhibitor (A2Ari).

### Claim 4 (depends on 3)

The method of claim 3, wherein the A2A receptor inhibitor is SCH58261.

### Claim 5 (depends on 3)

The method of claim 3, wherein the anti-CD73 antibody or antigen-binding fragment thereof and the A2Ari are administered concurrently.

### Claim 6 (depends on 3)

The method of claim 3, wherein the anti-CD73 antibody or antigen-binding fragment thereof is administered prior to the A2Ari.

### Claim 7 (depends on 3)

The method of claim 3, wherein the A2Ari is administered prior to the anti-CD73 antibody or antigen-binding fragment thereof.

### Claim 8 (depends on 3)

The method of claim 3, wherein the tumor is a lung cancer.

### Claim 9 (depends on 3)

The method of claim 3, wherein said method results in an increase in overall survival as compared to the administration of any one of the anti-CD73 antibody or the A2Ari alone.

### Claim 10 (depends on 3)

The method of claim 3, wherein the said method induces or increases a tumor-specific immune response.

### Claim 11 (depends on 3)

The method of claim 3, wherein the said method reduces the immunosuppressive effects of a AMP/CD73/adenosine pathway.

### Claim 12 (depends on 3)

The method of claim 3, wherein the said method reduces metastasis or reduces the propensity of the tumor to metastasize relative to the administration of either the anti-CD73 antibody or the A2Ari alone.

### Claim 13 (depends on 3)

The method of claim 3, wherein the said method reduces the number of metastases within the subject.

### Claim 14 (depends on 3)

The method of claim 3, wherein the subject is a human patient.

### Claim 15 (depends on 3)

The method of claim 3, wherein the tumor is a CD73 overexpressing tumor.